The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease

Research output: Contribution to journal › Review › Research › peer-review

Standard

The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease. / Galsgaard, Katrine D.

In: Journal of Clinical Medicine, Vol. 9, No. 12, 4049, 2020.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Galsgaard, KD 2020, 'The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease', Journal of Clinical Medicine, vol. 9, no. 12, 4049. https://doi.org/10.3390/jcm9124049

APA

Galsgaard, K. D. (2020). The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 9(12), [4049]. https://doi.org/10.3390/jcm9124049

Vancouver

Galsgaard KD. The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine. 2020;9(12). 4049. https://doi.org/10.3390/jcm9124049

Author

Galsgaard, Katrine D. / The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease. In: Journal of Clinical Medicine. 2020 ; Vol. 9, No. 12.

Bibtex

@article{b4803d36b6e049bd8793390b27efb8f4,
title = "The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease",
abstract = "A key criterion for the most common chronic liver disease-non-alcoholic fatty liver disease (NAFLD)-is an intrahepatic fat content above 5% in individuals who are not using steatogenic agents or having significant alcohol intake. Subjects with NAFLD have increased plasma concentrations of glucagon, and emerging evidence indicates that subjects with NAFLD may show hepatic glucagon resistance. For many years, glucagon has been thought of as the counterregulatory hormone to insulin with a primary function of increasing blood glucose concentrations and protecting against hypoglycemia. However, in recent years, glucagon has re-emerged as an important regulator of other metabolic processes including lipid and amino acid/protein metabolism. This review discusses the evidence that in NAFLD, hepatic glucagon resistance may result in a dysregulated lipid and amino acid/protein metabolism, leading to excess accumulation of fat, hyperglucagonemia, and increased oxidative stress contributing to the worsening/progression of NAFLD.",
keywords = "autophagy, amino acids, glucagon, NAFLD, the liver&#8211, alpha cell axis, CARNITINE PALMITOYLTRANSFERASE-I, PANCREATIC ALPHA-CELLS, AMINO-ACID-METABOLISM, RECEPTOR ANTAGONIST, BLOOD-GLUCOSE, POSTPRANDIAL HYPERGLYCEMIA, MALONYL-COA, RAT-LIVER, AUTOPHAGY, GLP-1",
author = "Galsgaard, {Katrine D.}",
year = "2020",
doi = "10.3390/jcm9124049",
language = "English",
volume = "9",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "M D P I AG",
number = "12",

}

RIS

TY - JOUR

T1 - The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease

AU - Galsgaard, Katrine D.

PY - 2020

Y1 - 2020

N2 - A key criterion for the most common chronic liver disease-non-alcoholic fatty liver disease (NAFLD)-is an intrahepatic fat content above 5% in individuals who are not using steatogenic agents or having significant alcohol intake. Subjects with NAFLD have increased plasma concentrations of glucagon, and emerging evidence indicates that subjects with NAFLD may show hepatic glucagon resistance. For many years, glucagon has been thought of as the counterregulatory hormone to insulin with a primary function of increasing blood glucose concentrations and protecting against hypoglycemia. However, in recent years, glucagon has re-emerged as an important regulator of other metabolic processes including lipid and amino acid/protein metabolism. This review discusses the evidence that in NAFLD, hepatic glucagon resistance may result in a dysregulated lipid and amino acid/protein metabolism, leading to excess accumulation of fat, hyperglucagonemia, and increased oxidative stress contributing to the worsening/progression of NAFLD.

AB - A key criterion for the most common chronic liver disease-non-alcoholic fatty liver disease (NAFLD)-is an intrahepatic fat content above 5% in individuals who are not using steatogenic agents or having significant alcohol intake. Subjects with NAFLD have increased plasma concentrations of glucagon, and emerging evidence indicates that subjects with NAFLD may show hepatic glucagon resistance. For many years, glucagon has been thought of as the counterregulatory hormone to insulin with a primary function of increasing blood glucose concentrations and protecting against hypoglycemia. However, in recent years, glucagon has re-emerged as an important regulator of other metabolic processes including lipid and amino acid/protein metabolism. This review discusses the evidence that in NAFLD, hepatic glucagon resistance may result in a dysregulated lipid and amino acid/protein metabolism, leading to excess accumulation of fat, hyperglucagonemia, and increased oxidative stress contributing to the worsening/progression of NAFLD.

KW - autophagy

KW - amino acids

KW - glucagon

KW - NAFLD

KW - the liver&#8211

KW - alpha cell axis

KW - CARNITINE PALMITOYLTRANSFERASE-I

KW - PANCREATIC ALPHA-CELLS

KW - AMINO-ACID-METABOLISM

KW - RECEPTOR ANTAGONIST

KW - BLOOD-GLUCOSE

KW - POSTPRANDIAL HYPERGLYCEMIA

KW - MALONYL-COA

KW - RAT-LIVER

KW - AUTOPHAGY

KW - GLP-1

U2 - 10.3390/jcm9124049

DO - 10.3390/jcm9124049

M3 - Review

C2 - 33333850

VL - 9

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 12

M1 - 4049

ER -

ID: 255113006